J02AX06 - Anidulafungin |
Propably not porphyrinogenic |
PNP |
Important Information
Risk for gastrointestinal adverse events in the form of diarrhoea, vomiting and nausea motivates vigilance against insufficient intake of food, especially of carbohydrate.
Side effects
Very common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are diarrhoea, vomiting and nausea.
Other common side effects are increased levels of alanine aminotransferase and aspartate aminotransferase.
Rationale
Anidulafungin is not a substrate, inducer or inhibitor of CYP enzymes.
Therapeutic characteristics
Anidulafungin is indicated for the treatment of invasive candidiasis in adult non-neutropenic patients.
Metabolism and pharmakokinetics
Anidulafungin is not metabolised in the liver (SPC). In vitro studies showed that the primary biotransformation of anidulafungin is mediated by slow chemical degradation. It is thought that anidulafungin and its degradation products are exclusively eliminated via biliary excretion (Damle 2009).
It is not a clinically relevant substrate, inducer or inhibitor of CYP450 isoenzymes (Damle 2009 and SPC).
References
- Scientific articles
- Damle BD, Dowell JA et al. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother. 2009 Mar;53(3):1149-56. PMID 19029327. #1705
- Summary of Product Characteristics
- Norwegian medicines agency. Summary of Product Characteristics (SPC). Anidulafungin. Last edition: date not listed. #1706
Similar drugs
© NAPOS 2024